Microlin Bio, a diagnostic and therapeutics biotech focusing on microRNA and its role in oncology, postponed its IPO on Wednesday. The recently-formed biotech had previously revised its terms several times, most recently adding warrants. It had planned to raise $28 million by offering 5.5 million units at a range of $4.50 to $5.50, and would have commanded a market cap of $51 million.